Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Aug 28, 2015
Last Price Change Open Day High 52-Week High
0.50  up   (0.961%) 52.52 55.23 120.96
Volume Previous Close Day Low 52-Week Low
1,096,800 52.01 51.68 15.00

View all »   RSSRecent Releases

Aug 17, 2015
Esperion Therapeutics Provides Update on the ETC-1002 Development Program Following End-of-Phase 2 Meeting With FDA

Aug 6, 2015
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2015 Financial Results